Jaakko Patrakka Selected Research

Puromycin Aminonucleoside

9/2014	Neph1 is reduced in primary focal segmental glomerulosclerosis, minimal change nephrotic syndrome, and corresponding experimental animal models of adriamycin-induced nephropathy and puromycin aminonucleoside nephrosis.
1/2010	Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jaakko Patrakka Research Topics

Disease

14	Proteinuria 01/2023 - 02/2001
7	Nephrotic Syndrome (Syndrome, Nephrotic) 11/2022 - 02/2002
5	Diabetic Nephropathies (Diabetic Nephropathy) 09/2023 - 01/2017
5	Kidney Diseases (Kidney Disease) 01/2023 - 02/2001
4	Albuminuria 09/2023 - 01/2011
4	IGA Glomerulonephritis (IGA Nephropathy) 01/2023 - 02/2001
4	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 09/2014 - 02/2001
4	Nephrosis 09/2014 - 02/2001
3	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 11/2022 - 08/2008
2	Glomerulonephritis 01/2022 - 02/2001
2	Inflammation (Inflammations) 01/2022 - 10/2021
2	Chronic Renal Insufficiency 10/2021 - 12/2020
2	Chronic Kidney Failure (Chronic Renal Failure) 08/2017 - 08/2015
2	Renal Insufficiency (Renal Failure) 08/2015 - 10/2011
2	congenital Nephrosis 05/2002 - 02/2001
1	Hyperglycemia 09/2023
1	Disease Progression 01/2023
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 10/2021
1	Fibrosis (Cirrhosis) 10/2021
1	Pathologic Processes 11/2020
1	Starvation 01/2018
1	Edema (Dropsy) 01/2013
1	Cysts 01/2013
1	Rupture 10/2004
1	Interstitial Nephritis (Tubulointerstitial Nephritis) 09/2002
1	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 02/2001
1	Nephritis 02/2001
1	Membranous Glomerulonephritis (Membranous Nephropathy) 02/2001

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 11/2022 - 10/2004
6	nephrinIBA 01/2010 - 02/2001
5	dendrinIBA 01/2023 - 08/2008
3	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2020
2	Immunoglobulin A (IgA)IBA 01/2022 - 10/2021
2	Puromycin AminonucleosideIBA 09/2014 - 01/2010
1	Blood Glucose (Blood Sugar)IBA 09/2023
1	Chalcone (Benzalacetophenone)IBA 09/2023
1	SulfonamidesIBA 09/2023
1	Karyopherins (Importin)IBA 01/2023
1	Complement System Proteins (Complement)IBA 01/2023
1	Immunoglobulin G (IgG)IBA 11/2022
1	AutoantibodiesIBA 11/2022
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2022
1	Transcription Factors (Transcription Factor)IBA 10/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2021
1	Mediator ComplexIBA 11/2020
1	Protamines (Protamine Sulfate)FDA Link 01/2019
1	Streptozocin (Streptozotocin)FDA Link 01/2018
1	Tyrosine (L-Tyrosine)FDA Link 01/2018
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2018
1	NPHS2 proteinIBA 08/2017
1	TRPC6 Cation ChannelIBA 08/2017
1	Vascular Endothelial Growth Factor BIBA 01/2017
1	MorpholinosIBA 01/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2014
1	ForminsIBA 02/2013
1	GTP Phosphohydrolases (GTPases)IBA 10/2011
1	CD2-associated proteinIBA 10/2011
1	Dynamins (Dynamin)IBA 10/2011
1	AlbuminsIBA 01/2011
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2011
1	ActininIBA 01/2010
1	LipopolysaccharidesIBA 01/2009
1	TinIBA 09/2002
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 05/2002
1	AntibodiesIBA 02/2002
1	Messenger RNA (mRNA)IBA 02/2001

Therapy/Procedure

1	Nephrectomy 01/2023
1	Renal Replacement Therapy (Therapies, Renal Replacement) 08/2015
1	Therapeutics 08/2009
1	Plasma Exchange 05/2007
1	Kidney Transplantation 05/2007